Pneumococcal disease
Drug research and approvals for pneumococcal disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 36 studies of pneumococcal disease are recruiting on ClinicalTrials.gov, and Health Canada has authorized 11 drug trials for it since 2013.
- Recruiting worldwide: 36
- Trials authorized in Canada: 11
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 36 recruiting on ClinicalTrials.gov ↗
- A Study to Evaluate 20vPnC in Healthy Chinese InfantsNCT07754539 · Phase 3 · Pfizer · starts Jul 25, 2026
- Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and…NCT07660198 · Phase 3 · Pfizer · starts Jun 15, 2026
- A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.NCT07629440 · Phase 3 · Pfizer · starts May 29, 2026
- Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)NCT07600983 · Phase 1 / Phase 2 · CanSino Biologics Inc. · starts May 24, 2026
- A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy InfantsNCT07573462 · Phase 3 · Pfizer · starts May 4, 2026
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveNCT07358910 · Not reported · Institut Pasteur du Cambodge · starts Dec 18, 2025
- Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of AgeNCT07348692 · Phase 3 · Sanofi · starts Jan 20, 2026
- Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 YearsNCT07300644 · Phase 2 · Sinovac Life Sciences Co., Ltd. · starts Nov 25, 2025
- A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)NCT07300267 · Phase 1 · Merck Sharp & Dohme LLC · starts Jan 13, 2026
The 10 newest of 11; search them all in Canada trials
| May 22, 2026 | A phase 3, randomized, double-blinded trial to evaluate the safety and tolerability of a multivalent pneumococcal conjugate vaccine in healthy infantsPF-07872412 (25-VALENT pneumococcal conjugate (25VPNC) vaccine) | Pfizer | Ongoing |
| Dec 20, 2023 | A phase 3, randomized, double-blind study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of…V116 (pneumococcal 21-VALENT conjugate vaccine) | Merck & Co. (MSD) | Ongoing |
| Sep 20, 2023 | A phase 2 multicenter, randomized, active-controlled, observer-blind, dose-ranging study to evaluate the safety, tolerability, and immunogenicity of a…Pneumococcal 25-VALENT conjugate vaccine (ivt PCV-25) | Inventprise Inc. | Ongoing |
| Dec 16, 2022 | A phase 3, randomized, double-blind, active comparator-controlled clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in…V116 / Vaxneuvance / Pneumovax 23 | Merck & Co. (MSD) | Ongoing |
| Jul 8, 2022 | A phase 3 clinical study to evaluate the safety, tolerability,and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or olderV116 / Vaxneuvance (PCV15) / Pneumovax 23 (PPSV23) | Merck & Co. (MSD) | Ongoing |
| Sep 25, 2020 | Safety and immunogenicity of a pneumococcal conjugate vaccine when administered concomitantly with routine pediatric vaccines in healthy toddlers and infantsSP0202 - multivalent pneumococcal conjugate vaccine (PCV) / Prevnar13 | Sanofi | Pending |
| Apr 15, 2020 | A phase 3, randomized, double-blind trial to evaluate the safety of a 20-valent pneumococcal conjugate vaccine in healthy infantsPF-06482077 (20-VALENT pneumococcal conjugate vaccine [20VPNC]) | Pfizer | Closed |
| Jul 3, 2019 | A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 in…V114 | Merck & Co. (MSD) | Ongoing |
| Nov 28, 2018 | A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants…V114 | Merck & Co. (MSD) | Ongoing |
| Jul 16, 2018 | A phase 3, multicenter, randomized, double-blind, active comparatorcontrolled study to evaluate the safety, tolerability, and immunogenicity of V114 followed…V114 | Merck & Co. (MSD) | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA